Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19
Shots: The P-II MOONSONG trial evaluates the antiviral activity, safety & PK of AT-527 (550/1100 mg, bid) vs PBO in adult patients with COVID-19. The therapy is jointly developed in collaboration with Roche The trial did not meet its 1EPs of reduction from baseline in SARS-CoV-2 virus in an overall study population, two-thirds of patients […]